Free Trial

Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Ontario Teachers Pension Plan Board

Hologic logo with Medical background

Key Points

  • The Ontario Teachers Pension Plan Board increased its stakes in Hologic, Inc. by **63.9%**, acquiring **24,511 shares**, bringing its total holding to **62,877 shares** valued at approximately **$3.88 million**.
  • Hologic reported a **net income of $1.08 EPS**, surpassing analyst expectations of $1.05, with a quarterly revenue of **$1.02 billion**, reflecting a **1.2% year-over-year growth**.
  • Analyst ratings for Hologic are mixed, with ten holding a **"hold" rating**, seven giving a **"buy,"** and one a **"strong buy,"** while the average target price sits at **$77.83**.
  • Want stock alerts on Hologic? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Ontario Teachers Pension Plan Board lifted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 63.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,877 shares of the medical equipment provider's stock after purchasing an additional 24,511 shares during the quarter. Ontario Teachers Pension Plan Board's holdings in Hologic were worth $3,884,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of HOLX. Victory Capital Management Inc. raised its holdings in Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after purchasing an additional 1,692,177 shares in the last quarter. Invesco Ltd. grew its position in shares of Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after acquiring an additional 572,187 shares during the last quarter. Northern Trust Corp grew its position in shares of Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after acquiring an additional 668,086 shares during the last quarter. Hsbc Holdings PLC grew its position in shares of Hologic by 12.5% during the fourth quarter. Hsbc Holdings PLC now owns 2,770,281 shares of the medical equipment provider's stock worth $199,723,000 after acquiring an additional 307,109 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Hologic by 6.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,625,290 shares of the medical equipment provider's stock worth $189,264,000 after acquiring an additional 169,427 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

HOLX has been the subject of several recent research reports. UBS Group increased their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Mizuho set a $75.00 target price on Hologic in a report on Thursday, July 31st. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Hologic presently has an average rating of "Moderate Buy" and an average price target of $77.83.

Read Our Latest Research Report on Hologic

Hologic Price Performance

Hologic stock traded down $0.18 during midday trading on Monday, reaching $67.89. 428,044 shares of the company were exchanged, compared to its average volume of 2,820,625. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a market capitalization of $15.10 billion, a price-to-earnings ratio of 28.15, a P/E/G ratio of 2.47 and a beta of 0.49. The firm's 50-day simple moving average is $65.09 and its 200-day simple moving average is $62.63. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the previous year, the business earned $1.06 EPS. The company's revenue for the quarter was up 1.2% on a year-over-year basis. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Should You Invest $1,000 in Hologic Right Now?

Before you consider Hologic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.

While Hologic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines